BACKGROUND Vasopressor agents could have certain specific effects in patients with cardiogenic shock (CS) after
Norepinephrine and epinephrine are currently the most commonly used vasopressor agents in clinical practice (4, (9) (10) (11) (12) . Studies comparing epinephrine and norepinephrine in patients with septic shock found no significant differences in outcome (13) . Nevertheless, these drugs may have certain specific effects in patients with CS that could influence outcome.
Norepinephrine is likely less thermogenic than epinephrine and therefore may have a more desirable effect on myocardial oxygen consumption (14). During acute ischemic CS, norepinephrine induces favorable effects on myocardial function (15, 16) .
Conversely, epinephrine may induce a higher cardiac index and deliver available nutrients very rapidly to the heart through lactate production (17) . Two retrospective studies further suggested that epinephrine may have deleterious effects associated with greater circulating cardiovascular biomarkers in patients with CS (10, 18) . Moreover, despite these potential negative warnings, epinephrine is still used to treat the most severe forms of CS after myocardial infarction. However, none of these findings has been assessed prospectively in this specific clinical setting.
The recent scientific statement from the American Heart Association recommends performing RCTs to identify the optimal vasopressor regimen in these patients (19) . In light of this information, the present prospective, double-blind, multicenter RCT was designed to compare both the hemodynamic efficacy and tolerance of epinephrine and norepinephrine in patients with CS secondary to percutaneous coronary intervention (PCI)-treated AMI. Plasma samples were collected at H0, H24, H48, and H72; they were stored at the study sites at -20 C,
METHODS
followed by storage at -80 C at the central laboratory.
Growth differential factor 15, plasma high-sensitivity troponin T levels, and N-terminal pro-B-type natriuretic peptide levels were measured. (A) Mean arterial pressure; (B) cardiac index; (C) heart rate; (D) stroke volume index; and (E) refractory cardiogenic shock distribution. Table 1 and Online Table 1 .
With the exception of sex, there was no difference between the 2 groups. Eleven patients (41%) in the epinephrine group and 18 patients (60%) in the norepinephrine group were successfully resuscitated after a cardiac arrest before enrollment in the study (p ¼ 0.19). At inclusion, 56 (98%) of 57 patients were mechanically ventilated. Coronary and PCI characteristics are described in Online Table 2 .
In all studied patients, urgent PCI revasculariza- Table 3 ).
For the main safety endpoint, epinephrine was associated with a higher incidence of refractory CS (10 Table 2 ). Given the higher incidence of refractory shock in the epinephrine group, the data and safety monitoring board terminated the study prematurely. Importantly, this adverse event was not planned as the primary safety outcome at trial initiation. It was, however, systematically recorded as an outcome of interest and carefully reviewed after the vigilance team of the trial identified an unexpected high rate of this outcome during the first year of the study. As a consequence, although this event was not defined before trial initiation, it was nonetheless defined during the course of the trial. Levy et al. Table 4 ). The evolution of SAP (p ¼ 0.11), diastolic arterial pressure (p ¼ 0.13), and MAP (p ¼ 0.80) during the first 3 days of the study was similar between groups (Online Table 5 ).
Mean heart rate increased significantly in the epinephrine group, whereas it did not change significantly in the norepinephrine group (p ¼ 0.031) (Central Illustration, Online Table 3 Table 5 Table 4 ).
Regarding metabolic changes, during the first 24 h, epinephrine use was associated with metabolic acidosis (p ¼ 0.0004) and increased lactate level (p < 0.0001) (Figure 2) , whereas arterial pH increased and lactate level decreased in the norepinephrine group.
Lactate clearance was observed much earlier and occurred at a faster pace in the norepinephrine group (p < 0.0001). The evolution of SVO 2 (p ¼ 0.20) (Online Table 3 ), oxygen consumption index (p ¼ 0.67) and oxygen delivery index (p ¼ 0.69) during the study period was similar between the 2 groups (Online Table 5 ).
Regarding organ dysfunction, the SOFA score and its components did not differ between the 2 groups, either at inclusion or during patient course (p ¼ 0.44).
There were no differences in variations during the study period with regard to creatinine, urea, diuresis, aspartate transaminase, and bilirubin levels between the 2 groups (Online Table 6 Table 2) . Epinephrine use was associated with a trend toward an increased risk of death on day 7 (p ¼ 0.08) and with a significantly higher risk of death or ECLS requirement on day 7 (p ¼ 0.031) (Online Figure 2) .
There was also a trend for an increased risk of death or ECLS requirement on day 28 (p ¼ 0.064). Post hoc results including ECLS implantation are further described in Online Table 7 . Epinephrine was associated with a marked and sustained increase in heart rate compared with norepinephrine-treated patients. This outcome was likely due to the high number of beta 2 -adrenoceptors present in the atria (approximately 30% of
The tachycardia observed in the epinephrine group led to a transient increase in cardiac index from H0 to H4, whereas stroke index was similar in both groups.
Importantly, epinephrine-treated patients exhibited substantial lactic acidosis, an increased cardiac double product (which can be considered as a surrogate of myocardial oxygen consumption) (26) , and similar perfusion markers such as SVO 2 and arteriovenous PCO 2 . Thus, it is highly likely that all of these effects were linked to receptor affinity differences because only epinephrine acts on beta 2 -receptors (27) . Experimentally, the main difference between the 2 drugs is that epinephrine increases the contractile force of myocardial fibers to a lesser degree than norepinephrine at the expense of a higher energy cost leading to lower cardiac efficiency (28) . Moreover, when used at higher doses, epinephrine is associated with negative inotropic effects. We and others have
shown that epinephrine-induced lactic acidosis is a cost-energy mechanism mainly related to the activation of the sarcolemmal sodium-potassium adenosine triphosphatase pump through beta 2 -receptors and cAMP (cyclic adenosine monophosphate) production in an adenosine triphosphate-consuming process (29, 30) . STUDY LIMITATIONS. The main limitation is that our study lasted 4 years and included only 57 patients during this period. Two reasons may explain this low inclusion rate. First, at the time of the study, the concept of a cardiac center and heart team was not developed in France. Therefore, in the same hospital, a patient with CS secondary to myocardial infarction might have been treated in a different ICU, leading to a relatively low incidence of this pathology in 1 specific ICU. Second, the mandatory use of a pulmonary artery catheter at the time, which is currently rarely used in France for shock monitoring, markedly limited the number of potential centers involved in the study. Nevertheless, our studied population was similar to studies assessing the most severe presentations of CS related to AMI both for clinical characteristics and mortality (1, 19, 35, 36) . Finally, the increase in cardiac index and heart rate associated with lactic acidosis has been described with epinephrine use in both septic (37) , hemorrhagic, and cardiogenic (38) shock. Nevertheless, because CS encompasses a wide spectrum of hemodynamic states (19) , the potential deleterious effects associated with its use such as refractory CS may differ in CS due to other etiologies (e.g., poisoning, postcardiopulmonary bypass, myocarditis).
CONCLUSIONS
In patients with CS secondary to acute MI, the use of epinephrine compared with norepinephrine was associated with similar effects on arterial pressure and cardiac index and a higher incidence of refractory shock. 
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